HOTBIO - A Holistic Approach to Training a new Generation of Scientists in Marine Biodiscovery

HOTBIO财团将培养新一代的早期科学家，将海洋微生物天然产物从海底带到床边。他们将参与从微生物分离到化合物纯化和鉴定到制造具有理想药物性质的类似物的管道的每个阶段。他们将获得获取和惠益分享、知识产权和创业方面的相关技能。从HOTBIO毕业的学生将处于进入具有挑战性的劳动力市场的独特地位，因为他们将在学术界和行业合作伙伴的世界领先研究小组接受多学科培训。导师将由工业科学家和MSCA ITN MarPipe的应届毕业生提供。HOTBIO财团由来自七个欧洲国家的八名受益人组成，其中包括两名来自非学术部门的成员，将接待十名博士生。另外三名博士生将由瑞士国家教育、研究和创新秘书处资助。除了在欧洲的合作伙伴借调，学生还将有机会在非洲和亚洲的中低收入国家（LMICs）做借调，以更深入地了解如何在资源有限的环境中进行现代研究。HOTBIO扩展了传统的海洋生物发现管道，包括计算机辅助药物设计（CADD），优化化合物的化学合成（即药物化学），目标解卷积和广泛的ADMET分析。这将推动生物活性微生物次级代谢产物进入临床前开发的后期阶段，也将为药物发现过程的初始阶段应该靶向哪种化合物的决策和优先级提供信息。下游开发将包括早期项目的热门化合物。

The HOTBIO consortium will train a new generation of early-stage scientists to take marine microbial natural products from the seabed to the bedside. They will be involved in every stage of the pipeline from microbial isolation through compound purification and identification to making analogues with desirable drug-like properties. They will gain associated skills in access and benefit sharing, intellectual property and entrepreneurship. Students graduating from HOTBIO will be in a unique position to enter a challenging labour market as they will have received multidisciplinary training at world leading research groups in academia as well as at industry partners. Mentorship will be provided by industrial scientists and recent graduates from the MSCA ITN MarPipe. The HOTBIO consortium consists of eight beneficiaries from seven European countries, including two members from non-academic sectors, that will host ten PhD students. Three more PhD students hosted by two Swiss associated partners will be funded by the Swiss State Secretariat for Education, Research and Innovation. In addition to secondments at the partners in Europe, students will also get the opportunity to do secondments in low-to-middle income countries (LMICs) in Africa and Asia to get a deeper understanding of how modern research can be done in resource-limited setting. HOTBIO expands a conventional marine biodiscovery pipeline by including computer aided drug design (CADD), chemical synthesis of optimized compounds (i.e. medicinal chemistry), target deconvolution and extensive ADMET profiling. This will advance the bioactive microbial secondary metabolites to the later stages of preclinical development, and it will also inform the decisions and priorities of what kind of compounds that should be targeted in the initial phase of the drug discovery process. The downstream development will include hit compounds from earlier projects.